• Skip to primary navigation
  • Skip to main content
  • Skip to footer
ATDC

ATDC

Menu
  • About
    • Impact
    • Team
    • Sponsors & Partners
    • Mentors
    • Contact Us
    • Locations
      • ATDC HQ (Midtown Atlanta)
      • ATDC @ ALPHARETTA
      • ATDC @ ATHENS
      • ATDC @ AUGUSTA
      • ATDC @ FORSYTH COUNTY
      • ATDC @ PEACHTREE CORNERS
      • ATDC @ SAVANNAH
  • How We Help
    • Overview
    • Classes
    • Capital
    • Customers
    • Georgia Tech Resources
  • Portfolio
    • Overview
    • Criteria
    • ATDC Accelerate
    • ATDC Signature
    • Graduates
    • Testimonials
  • Industry Vertical Markets
    • 5G
  • Events
  • News + Jobs
    • News
    • ATDC Company Job Board
  • Login
  • Join

Tikvah Raises $10 Million

ATDC member company Tikvah Therapeutics, Inc, a biopharmaceutical company that focuses on novel therapeutic treatments for diseases of the central nervous system, including neurology and psychiatric disorders, announced today it has completed a private financing with gross proceeds of $10 million in a convertible note financing. Proceeds from the financing will be used to accelerate development of the company's lead products. "This financing provides us with resources to continue the planned advancement of Tikvah's robust pipeline of central nervous system and neurology drug candidates," said Dr. Harold H. Shelvin, President...

November 30, 1999 by ATDC

Logo
ATDC member company Tikvah Therapeutics, Inc, a biopharmaceutical company that focuses on novel therapeutic treatments for diseases of the central nervous system, including neurology and psychiatric disorders, announced today it has completed a private financing with gross proceeds of $10 million in a convertible note financing. 

Proceeds from the financing will be used to accelerate development of the company’s lead products. "This financing provides us with resources to continue the planned advancement of Tikvah’s robust pipeline of central nervous system and neurology drug candidates," said Dr. Harold H. Shelvin, President and CEO of Tikvah. "In the coming months, we plan to move forward with Investigational New Drug applications for our two lead products as well as continue to vigorous acquisition of additional later stage and pipeline products."

Category iconNews from Our Companies Tag iconVenture Capital

What is ATDC?

Footer

  • Facebook
  • Instagram
  • LinkedIn
  • Twitter
  • YouTube

© Copyright 1986 - 2023. Advanced Technology Development Center.
All Rights Reserved.
Tech Square  |  75 5th Street NW, Suite 2000  |  Atlanta, GA 30308
t: (404) 894-3575  |  f: (404) 894-4545 Terms of Use | Contact Us